11 results
To assess the efficacy, safety and cost-effectiveness of the CYP2C19 genotype guided antiplatelet treatment strategy, using clopidogrel or prasugrel/ticagrelor.
To assess the safety, efficacy and net clinical benefit of clopidogrel versus the new antiplatelet drugs i.e. ticagrelor and prasugrel in patients older than 70 years.
To evaluate the efficacy of NEOD001 plus standard of care vs. placebo plus standard of care when administered intravenously in subjects with AL amyloidosis by assessing time to all-cause mortality or cardiac hospitalizationSecondary ObjectivesIn…
To determine if ticagrelor at treatment steady state will be associated to an improved microvascular function as compared to prasugrel in revascularized STEMI patients.
Ticagrelor, at steady state (i.e. after 30 days), will be associated to an improved endothelial function as compared to clopidogrel or prasugrel.
To evaluate the effect of AMG 334 compared to placebo on the change from baseline in mean monthly migraine days, in subjects with episodic migraine.hypothesis: In subjects with episodic migraine, AMG 334 has a greater reduction from baseline in mean…
To evaluate safety of 3-months versus standard 12-months of DAPT
The primary objective of this study is to demonstrate non-inferiority by pharmacodynamic (PD) analysis of the prasugrel 5-mg maintenance dose (MD) in aspirin-treated subjects <60 kg with stable coronary artery disease (CAD) versus the…
The primary objective of this study is to demonstrate non-inferiority by pharmacodynamic (PD) analysis of the prasugrel 5-mg maintenance dose (MD) in aspirin-treated subjects >=75 years of age with stable coronary artery disease (CAD) versus…
The purpose of this study is to determine the safety and efficacy of AMG 334 compared to placebo in episodic migraine patients who havepreviously failed 2 to 4 prophylactic migraine treatments and therefore have a high unmet medical need.
The primary objective of this study is to assess the feasibility and safety of a single antiplatelet strategy with prasugrel or ticagrelor prior to, during and after PCI with a new generation drug-eluting in non-ST-elevation acute coronary syndrome…